UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D. C. 20549
                                    FORM 8-K


                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
                                 OCTOBER 3, 2006
                              MACROCHEM CORPORATION
             (Exact name of registrant as specified in its charter)


           DELAWARE                      0-13634               04 2744744
(State or other jurisdiction of  (Commission file number)    (IRS employer
 incorporation or organization)                           identification number)



           40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS, MA 02481
 ------------------------------------------------------------------------------
               (Address of Principal Executive Offices) (Zip Code)

       Registrant's telephone number, including area code: (781) 489-7310


  ------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

__Written communications pursuant to Rule 425 under the Securities Act
  (17 CFR 230.425)
__Soliciting material pursuant to rule 14a-12 under the Exchange Act
  (17 CFR 240.14a-12)
__Pre-commencement communications pursuant to rule 14d-2(b)
  under the Exchange Act (17 CFR 240.14d-2(b))
__Pre-commencement communications pursuant to rule 13e-4(c)
  under the Exchange Act (17 CFR 240.13e-4(c))







ITEM 8.01.    OTHER EVENTS.


     On October 3, 2006,  MacroChem  Corporation  announced the  initiation of a
Phase II trial of its EcoNail(TM)  topical  antifungal  lacquer in patients with
onychomycosis.  A copy of the press  release  announcing  the  initiation of the
Phase II EcoNail  trial is attached  hereto as Exhibit 99.1 and is  incorporated
herein by reference.


ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.


Exhibits Description


         99.1     Press release, dated October 3, 2006



                                    SIGNATURE


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                            MACROCHEM CORPORATION



Dated:  October 4, 2006        By:  /s/ Robert J. DeLuccia
                                  ----------------------------------------------
                                  Name:    Robert J. DeLuccia
                                  Title:   President and Chief Executive Officer







                                  EXHIBIT INDEX


The following exhibits are filed herewith:


     99.1  Press Release, dated October 3, 2006